

COVID-19 VACCINES

COVID-19 Vaccines: An overview prepared by EAHP

This is a summary compiled by EAHP on publicly available information on the main COVID-19 vaccines which are currently being developed. Read the latest version **updated on 3 February 2021** [HERE](#)^[1]

European Medicines Agency

The European Medicines Agency (EMA) has made published the following information for authorised COVID-19 vaccines: the assessment report of the Committee for Medicinal Products for Human Use (CHMP), the medicines overview (translated in all EU languages), the product information (translated in all EU languages) and the full body of the core Risk Management Plan.

Access this information for:

- [Comirnaty](#) ^[2]
- [COVID-19 Vaccine Moderna](#)^[3]
- [COVID-19 Vaccine AstraZeneca](#)^[4]

For Comirnaty, EMA has made available additional information: [Information on extra dose from vials of Comirnaty COVID-19 vaccine](#)^[5] | [First COVID-19 vaccine safety update](#)^[6] | [Clarification of Comirnaty dosage interval](#) ^[7]

EMA has made available an array of information on COVID-19, including information on treatments and vaccines.

- [COVID-19 vaccines: key facts](#) ^[8]
- [COVID-19 vaccines: development, evaluation, approval and monitoring](#) ^[9]
- [COVID-19 vaccines: studies for approval](#) ^[10]

A public stakeholder meeting on COVID-19 vaccines was organised by EMA on 11 December 2020. The recording of this meeting and all materials are available [HERE](#) ^[11].

A second public stakeholder meeting on COVID-19 vaccines was held on 8 January 2021.

Find all information HERE ^[12].

European Commission

- **Webpage on safe COVID-19 vaccines for Europeans** ^[13]

The webpage contains information about how vaccines work, the health benefits of vaccines, the authorisation process, their long-term safety and the EU's current portfolio. The information on the webpage is translated into all EU languages.

European Vaccination Information Portal (EVIP)

- **Dedicated section on COVID-19 vaccines** ^[14]

The EVIP dedicated section shares information on the benefits of COVID-19 vaccines. Translations into all EU languages are available.

The disclaimer for the EAHP COVID-19 Resource Centre can be found here ^[15]

Last update: 5 February 2021

Links

[1] https://www.eahp.eu/sites/default/files/covid-19_vaccines_an_overview_prepared_by_eahp_0.pdf

[2] <https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty>

[3] <https://www.ema.europa.eu/en/medicines/human/summaries-opinion/covid-19-vaccine-moderna>

[4] <https://www.ema.europa.eu/en/medicines/human/summaries-opinion/covid-19-vaccine-astrazeneca>

[5] <https://www.ema.europa.eu/en/news/extra-dose-vials-comirnaty-covid-19-vaccine>

[6] <https://www.ema.europa.eu/en/news/first-covid-19-vaccine-safety-update-published>

[7] <https://www.ema.europa.eu/en/news/clarification-comirnaty-dosage-interval>

[8] <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-key-facts>

[9] <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring>

[10] <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-studies-approval>

[11] <https://www.ema.europa.eu/en/events/public-stakeholder-meeting-development-authorisation-safe-effective-covid-19-vaccines-eu>

[12] <https://www.ema.europa.eu/en/events/public-stakeholder-meeting-approval-roll-out-covid-19-vaccines-eu>

[13] https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en

[14] <https://vaccination-info.eu/en/covid-19>

[15] <https://www.eahp.eu/hp-practice/hospital-pharmacy/eahp-covid-19-resource-centre>